Access to Larotrectinib for Treating Cancers with NTRK Gene Fusion

Sponsor: Bayer

Expanded Access
Approved for Marketing
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT03025360

Provider View

This program provides access to the drug larotrectinib for patients with cancers that have a specific genetic change called NTRK gene fusion, who cannot join existing clinical trials for this treatment.

Patient Parameters

Program Overview

This program is designed to help patients with cancer that have a specific genetic change known as NTRK gene fusion. This change happens when parts of two different genes join together, which can lead to the growth of tumors in various parts of the body. Larotrectinib is a medication that targets and blocks the action of this gene fusion. The program is for patients who cannot join current clinical trials for larotrectinib and have not responded to standard treatments for their cancer.

Eligibility Criteria

Inclusion Criteria

  • Have a cancer diagnosis with an NTRK1, NTRK2, or NTRK3 gene fusion.
  • Cannot participate in an ongoing larotrectinib clinical trial.
  • Medically suitable to receive treatment with larotrectinib.

Exclusion Criteria

  • Currently participating in a clinical study involving larotrectinib or another similar drug.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.